NASDAQ:VTRS Viatris Q3 2026 Earnings Date & Estimates $17.44 -0.05 (-0.29%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$17.45 +0.01 (+0.05%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Viatris is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Viatris in Q3 2026Viatris is expected to post earnings of $0.65 per share on revenue of $3.80 billion. In the same quarter a year earlier Viatris reported $0.67 per share on revenue of $3.76 billion. Viatris last reported on August 6, 2026, posting $0.69 per share and beating the $0.60 consensus estimate. Viatris has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.65Expected Revenue$3.80 billionPrior-Year EPS$0.67Prior-Year Revenue$3.76 billionExpected EPS Growth-3.7%Expected Revenue Growth+1.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.69 (Beat by +$0.09)Last Quarter Revenue$3.76 billionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Viatris Q3 2026 Earnings FAQ When does Viatris report Q3 2026 earnings? Viatris (NASDAQ:VTRS) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Viatris' Q3 2026 earnings call? Viatris' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Viatris? Analysts expect Viatris to post earnings of $0.65 per share for Q3 2026. How much revenue is Viatris expected to report? The consensus revenue estimate for Viatris is $3.80 billion for Q3 2026. Viatris Earnings HeadlinesViatris To Acquire Pacira BioSciences: What Investors Should Know40 minutes ago | seekingalpha.comViatris (VTRS) Buys Pacira As Fair Value Stays In Focus40 minutes ago | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 9 at 1:00 AM | Banyan Hill Publishing (Ad)Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion.October 8 at 10:13 PM | marketscreener.comMPacira Biosciences snags $1.65 billion Viatris takeover deal; shares flyOctober 8 at 10:13 PM | msn.comWhy Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?October 8 at 10:13 PM | finance.yahoo.comSee More Viatris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viatris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viatris and other key companies, straight to your email. Email Address About ViatrisViatris (NASDAQ:VTRS) (NASDAQ:VTRS) is a global healthcare company that develops, manufactures and commercializes medicines across a broad range of therapeutic areas. Its portfolio includes generic and branded medicines, over-the-counter products, biosimilars and active pharmaceutical ingredients. The company supplies treatments for cardiovascular disease, infectious diseases, central nervous system conditions, immunology, oncology and other areas of healthcare. Viatris was formed in November 2020 through the combination of Mylan N.V. and Pfizer’s Upjohn business. The transaction brought together Mylan’s generics and biosimilars operations with Upjohn’s established portfolio of off-patent branded medicines. The company also offers manufacturing, regulatory and commercial capabilities intended to support the availability of medicines throughout their product life cycles. Based in Pittsburgh, Pennsylvania, Viatris serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, emerging markets and other international regions. The company’s global portfolio includes both widely used generic medicines and established brands, allowing it to serve pharmacies, hospitals, distributors and other healthcare customers.View Viatris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Applied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to Change Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
